- Evaluation of the hepatitis C virus-infected patient: the initial encounterNorbert Brau
Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA
Clin Infect Dis 56:853-60. 2013..Initial counseling on therapy emphasizes viral cure rates of currently 70%-80% as well as expected side effects. New treatments with fewer side effects and potentially higher cure rates are currently in development...
- Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter studyNorbert Brau
Bronx Veterans Affairs VA Medical Center, Infectious Disease Section 111F, 130 West Kingsbridge Road, Bronx, NY 10468, USA
J Hepatol 47:527-37. 2007..HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC)...
- A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis CIra M Jacobson
Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, New York, New York 10021, USA
Am J Gastroenterol 100:2453-62. 2005....
- Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapyNorbert Brau
Department of Medicine, Division of Infectious Diseases, Mount Sinai School of Medicine, New York, NY 10468, USA
J Antimicrob Chemother 56:991-5. 2005..Given the safety and efficacy of combination therapy with peginterferon plus ribavirin and the deleterious effects of chronic hepatitis C, all HIV/HCV-coinfected patients should be evaluated for therapy...
- Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirinNorbert Brau
Bronx Veterans Affairs Medical Center, Bronx, NY, USA
Hepatology 39:989-98. 2004..Control of HIV infection improves rather than worsens during therapy...
- Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patientsMarie Louise C Vachon
Division of Liver Diseases, Mount Sinai School of Medicine, NY, USA
J Hepatol 54:41-7. 2011....
- Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfaDouglas T Dieterich
Mount Sinai School of Medicine, New York, New York 10029 6574, USA
Am J Gastroenterol 98:2491-9. 2003....
- Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infectionEdmund J Bini
VA New York Harbor Healthcare System and NYU School of Medicine, New York, New York 10010, USA
Am J Gastroenterol 100:1772-9. 2005..The aims of this study were to determine the proportion of HCV-infected veterans who were eligible for interferon alfa and ribavirin therapy and to evaluate barriers to HCV treatment...
- Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan areaNorbert Brau
Veterans Affairs Medical Center, Infectious Disease Section, Bronx, New York 10468, USA
Am J Gastroenterol 97:2071-8. 2002..The aims of this study were to determine the prevalence of hepatitis C virus (HCV) infection and its risk factors, as well as the prevalence of coinfection with HIV and its risk factors, among patients with confirmed HCV infection...
- Acquired factor VIII inhibitor in patients with hepatitis C virus infection and the role of interferon-alpha: a case reportZwi A Schreiber
Bronx Lebanon Hospital, Bronx, New York, USA
Am J Hematol 80:295-8. 2005..No previous case of factor VIII inhibitor in a patient infected with HIV has been reported...
- Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?Karen H Seal
VA Medical Center, San Francisco, CA 94121, USA
J Clin Gastroenterol 41:199-205. 2007..Many patients with a history of injection drug use (IDU) are excluded from hepatitis C virus (HCV) treatment. This prospective multicenter study aimed to determine the impact of IDU history on HCV treatment candidacy and outcomes...
- Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapyNorbert Brau
Infectious Diseases Section 111F, Bronx Veterans Affairs Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA
J Hepatol 44:47-55. 2006..This study examined whether HIV suppression through highly active antiretroviral therapy (HAART) attenuates this accelerated fibrosis progression...
- Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirinNorbert Brau
Mount Sinai School of Medicine, Bronx Veterans Affairs Medical Center, Infectious Diseases Section 111F, 130 West Kingsbridge Road, New York, NY 0468, USA
Semin Liver Dis 25:33-51. 2005..Given that pegylated interferon and ribavirin have been shown to be safe and effective for HIV/HCV coinfection as well as HCV monoinfection, all HIV/HCV-coinfected patients should be evaluated for therapy...
- National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infectionEdmund J Bini
VA New York Harbor Healthcare System and NYU School of Medicine, New York, NY, USA
J Clin Gastroenterol 40:732-9. 2006..Although HIV testing is recommended for persons with hepatitis C virus (HCV) infection who are at risk for HIV, little is known about HIV testing in this population...